Wild type N-ras displays anti-malignant properties, in part by downregulating decorin

Journal of Cellular Physiology

Volumn 227, Issue 6, 2012, Pages 2341-2351

  Benet, Marta ^a,c   Dulman, Robin Yates ^a,d   Suzme, Raffi ^a   de Miera, Eleazar Vega Saenz ^a   Vega, Martha E ^a   Nguyen, Thuy ^a   Zavadil, Jiri ^a,b   Pellicer, Angel ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECORIN; MESSENGER RNA; MICRORNA; RAS PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC TRANSFORMATION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CELL ADHESION; CELL CYCLE CHECKPOINTS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, VIRAL; DECORIN; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GENOTYPE; HUMANS; MALE; MICE; MICRORNAS; NEOPLASMS; NIH 3T3 CELLS; PHENOTYPE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84857469180     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22969     Document Type: Article

References (45)

1. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E. 1992. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360: 361-364.
2. Bos JL. 1997. Ras-like GTPases. Biochim Biophys Acta 1333: M19-M31.
3. Buck MB, Fritz P, Dippon J, Zugmaier G, Knabbe C. 2004. Prognostic significance of transforming growth factor beta receptor II in estrogen receptor-negative breast cancer patients. Clin Cancer Res 10: 491-498.
4. Calin GA, Croce CM. 2006. MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
5. Cartwright CA, Eckhart W, Simon S, Kaplan PL. 1987. Cell transformation by pp60c-src mutated in the carboxy-terminal regulatory domain. Cell 49: 83-91.
6. Corominas M, Perucho M, Newcomb EW, Pellicer A. 1991. Differential expression of the normal and mutated K-ras alleles in chemically induced thymic lymphomas. Cancer Res 51: 5129-5133.
7. Dalal BI, Keown PA, Greenberg AH. 1993. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 143: 381-389.
8. De Donatis A, Comito G, Buricchi F, Vinci MC, Parenti A, Caselli A, Camici G, Manao G, Ramponi G, Cirri P. 2008. Proliferation versus migration in platelet-derived growth factor signaling: The key role of endocytosis. J Biol Chem 283: 19948-19956.
9. Derynck R, Akhurst RJ. 2007. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol 9: 1000-1004.
10. Diamond LE, Guerrero I, Pellicer A. 1988. Concomitant K- and N-ras gene point mutations in clonal murine lymphoma. Mol Cell Biol 8: 2233-2236.
11. Diaz R, Ahn D, Lopez-Barcons L, Malumbres M, Perez de Castro I, Lue J, Ferrer-Miralles N, Mangues R, Tsong J, Garcia R, Perez-Soler R, Pellicer A. 2002. The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res 62: 4514-4518.
12. Diaz R, Lopez-Barcons L, Ahn D, Garcia-Espana A, Yoon A, Matthews J, Mangues R, Perez-Soler R, Pellicer A. 2004. Complex effects of Ras proto-oncogenes in tumorigenesis. Carcinogenesis 25: 535-539.
13. Diaz R, Lue J, Mathews J, Yoon A, Ahn D, Garcia-Espana A, Leonardi P, Vargas MP, Pellicer A. 2005. Inhibition of Ras oncogenic activity by Ras protooncogenes. Int J Cancer 113: 241-248.
14. Gao CF, Xie Q, Su YL, Koeman J, Khoo SK, Gustafson M, Knudsen BS, Hay R, Shinomiya N, Vande Woude GF. 2005. Proliferation and invasion: Plasticity in tumor cells. Proc Natl Acad Sci USA 102: 10528-10533.
15. Guerrero I, Villasante A, Corces V, Pellicer A. 1985. Loss of the normal N-ras allele in a mouse thymic lymphoma induced by a chemical carcinogen. Proc Natl Acad Sci USA 82: 7810-7814.
16. Gupta GP, Massague J. 2006. Cancer metastasis: Building a framework. Cell 127: 679-695.
17. Hernandez-Munoz I, Benet M, Calero M, Jimenez M, Diaz R, Pellicer A. 2003. rgr oncogene: Activation by elimination of translational controls and mislocalization. Cancer Res 63: 4188-4195.
18. James RM, Arends MJ, Plowman SJ, Brooks DG, Miles CG, West JD, Patek CE. 2003. K-ras proto-oncogene exhibits tumor suppressor activity as its absence promotes tumorigenesis in murine teratomas. Mol Cancer Res 1: 820-825.
19. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. 2003. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
20. Kim IM, Ramakrishna S, Gusarova GA, Yoder HM, Costa RH, Kalinichenko VV. 2005. The forkhead box m1 transcription factor is essential for embryonic development of pulmonary vasculature. J Biol Chem 280: 22278-22286.
21. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massague J. 1990. Growth inhibition by TGF-beta linked to suppression of retinoblastoma protein phosphorylation. Cell 62: 175-185.
22. Lee MS, Moon EJ, Lee SW, Kim MS, Kim KW, Kim YJ. 2001. Angiogenic activity of pyruvic acid in in vivo and in vitro angiogenesis models. Cancer Res 61: 3290-3293.
23. Ma RY, Tong TH, Cheung AM, Tsang AC, Leung WY, Yao KM. 2005. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J Cell Sci 118: 795-806.
24. Malumbres M, Pellicer A. 1998. RAS pathways to cell cycle control and cell transformation. Front Biosci 3: d887-d912.
25. Mangues R, Symmans WF, Lu S, Schwartz S, Pellicer A. 1996. Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis. Oncogene 13: 1053-1063.
26. Massague J. 2008. TGFbeta in Cancer. Cell 134: 215-230.
27. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D, Seftor E, Hendrix MJ, Katsanis E, Akporiaye ET. 2001. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. Int J Cancer 91: 76-82.
28. Newcomb EW, Steinberg JJ, Pellicer A. 1988. ras oncogenes and phenotypic staging in N-methylnitrosourea- and gamma-irradiation-induced thymic lymphomas in C57BL/6J mice. Cancer Res 48: 5514-5521.
29. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, Massague J. 2008. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133: 66-77.
30. Park WH, Jung CW, Park JO, Kim K, Kim WS, Im YH, Lee MH, Kang WK, Park K. 2003. Trichostatin inhibits the growth of ACHN renal cell carcinoma cells via cell cycle arrest in association with p27, or apoptosis. Int J Oncol 22: 1129-1134.
31. Perez de Castro I, Benet M, Jimenez M, Alzabin S, Malumbres M, Pellicer A. 2005. Mouse p10, an alternative spliced form of p15INK4b, inhibits cell cycle progression and malignant transformation. Cancer Res 65: 3249-3256.
32. Riquelme C, Larrain J, Schonherr E, Henriquez JP, Kresse H, Brandan E. 2001. Antisense inhibition of decorin expression in myoblasts decreases cell responsiveness to transforming growth factor beta and accelerates skeletal muscle differentiation. J Biol Chem 276: 3589-3596.
33. Roberts AB, Wakefield LM. 2003. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100: 8621-8623.
34. Shizukuda Y, Tang S, Yokota R, Ware JA. 1999. Vascular endothelial growth factor-induced endothelial cell migration and proliferation depend on a nitric oxide-mediated decrease in protein kinase Cdelta activity. Circ Res 85: 247-256.
35. Takeuchi Y, Kodama Y, Matsumoto T. 1994. Bone matrix decorin binds transforming growth factor-beta and enhances its bioactivity. J Biol Chem 269: 32634-32638.
36. Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A. 2006. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174: 175-183.
37. Vos MD, Clark GJ. 2006. RASSF family proteins and Ras transformation. Methods Enzymol 407: 311-322.
38. Wakefield LM, Sporn MB. 1990. Suppression of carcinogenesis: A role for TGF-beta and related molecules in prevention of cancer. Immunol Ser 51: 217-243.
39. Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, Park HJ, Tan Y, Ackerson T, Costa RH. 2005. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 25: 10875-10894.
40. Welm AL. 2008. TGFbeta primes breast tumor cells for metastasis. Cell 133: 27-28.
41. Xaus J, Comalada M, Cardo M, Valledor AF, Celada A. 2001. Decorin inhibits macrophage colony-stimulating factor proliferation of macrophages and enhances cell survival through induction of p27(Kip1) and p21(Waf1). Blood 98: 2124-2133.
42. Zagzag D, Esencay M, Mendez O, Yee H, Smirnova I, Huang Y, Chiriboga L, Lukyanov E, Liu M, Newcomb EW. 2008. Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: One plausible explanation of Scherer's structures. Am J Pathol 173: 545-560.
43. Zavadil J, Bottinger EP. 2005. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24: 5764-5774.
44. Zavadil J, Narasimhan M, Blumenberg M, Schneider RJ. 2007. Transforming growth factor-beta and microRNA:mRNA regulatory networks in epithelial plasticity. Cells Tissues Organs 185: 157-161.
45. Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J, Anderson MW, Sills RC, Hong HL, Devereux TR, Jacks T, Guan KL, You M. 2001. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 29: 25-33.